{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:57Z","timestamp":1790040357099,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016610","name":"Andrew McDonough B+ Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA232486"],"award-info":[{"award-number":["U01CA232486"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA243072"],"award-info":[{"award-number":["U01CA243072"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coph.2025.102546","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:39:03Z","timestamp":1750300743000},"page":"102546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Precision medicine and immunotherapeutic approaches for relapsed\/refractory paediatric acute myeloid leukaemia"],"prefix":"10.1016","volume":"83","author":[{"given":"Caroline C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.coph.2025.102546_sref1","article-title":"Children's Oncology Group's 2023 blueprint for research: myeloid neoplasms","volume":"70","author":"Cooper","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.coph.2025.102546_sref2","first-page":"2275","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102546_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438690","article-title":"Navigating treatment options and communication in relapsed pediatric AML","volume":"44","author":"Graff","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"22","key":"10.1016\/j.coph.2025.102546_bib4","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.2024026598","article-title":"Precision medicine for high-risk gene fusions in paediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements","volume":"145","author":"Egan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A Phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.coph.2025.102546_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib7","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children's Oncology group","volume":"38","author":"Cooper","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102546_bib10","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/bjh.18844","article-title":"Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population","volume":"202","author":"Doan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coph.2025.102546_bib11","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282637","article-title":"Clinical responses in pediatric patients with relapsed\/refractory leukemia treated with azacitidine and venetoclax","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102546_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/hematology.2022000358","article-title":"The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3\/IDH\/BCL2 inhibitors, and other therapies","volume":"2022","author":"Pommert","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.coph.2025.102546_bib13","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1078-0432.CCR-21-4450","article-title":"Preclinical and pilot study of Type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication","volume":"28","author":"Inaba","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102546_bib14","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","article-title":"A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study","volume":"22","author":"Cooper","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102546_bib15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.15593","article-title":"A phase 1\/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia","volume":"185","author":"Zwaan","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coph.2025.102546_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajh.26510","article-title":"Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed\/refractory AML: report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium","volume":"97","author":"Pommert","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2025.102546_bib19","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-19-1251","article-title":"Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study","volume":"26","author":"Burke","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102546_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030496","article-title":"Nivolumab plus 5-azacitidine in pediatric relapsed\/refractory acute myeloid leukemia (AML): phase I\/II trial results from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2025.102546_sref21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102546_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_sref23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib29","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1056\/NEJMc2404110","article-title":"Response and resistance to menin inhibitor in UBTF-tandem duplication AML","volume":"390","author":"Tiong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102546_bib30","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_sref31","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102546_sref32","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3324\/haematol.2023.283817","article-title":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","volume":"109","author":"Naik","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102546_sref33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the innate immune system in pediatric and adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102546_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2018.191841","article-title":"Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-M\u00fcnster study group","volume":"104","author":"Niktoreh","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102546_bib35","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's Oncology group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib36","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology group trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib38","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_sref39","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood-2024-198419","article-title":"Favourable outcomes in newly diagnosed paediatric AML with gemtuzumab ozogamicin and risk-stratified therapy: results from the international phase III myechild 01 trial","volume":"144","author":"Gibson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162593","article-title":"Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102546_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009013","article-title":"Developing a membrane-proximal CD33-targeting CAR T cell","volume":"12","author":"Freeman","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102546_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102546_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children's Oncology group","volume":"40","author":"Lamble","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102546_bib45","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1182\/blood-2022-158029","article-title":"Safety and activity of flotetuzumab in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia: results from the COG PEPN1812 phase 1 trial","volume":"140","author":"Lamble","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib46","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1182\/blood-2022-163503","article-title":"Phase I study of tagraxofusp with or without chemotherapy in pediatric patients with relapsed or refractory CD123-expressing hematologic malignancies: a therapeutic advances in childhood leukemia and lymphoma (TACL) consortium trial","volume":"140","author":"Lamble","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib47","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102546_bib48","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S2666-6367(23)00184-7","article-title":"Preliminary results from a phase 1 trial showing safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML","volume":"29","author":"Naik","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coph.2025.102546_bib49","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2023-173162","article-title":"First-in-Human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics","volume":"142","author":"Bajel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102546_sref51","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102546_bib52","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.coph.2025.102546_bib53","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.1182\/blood-2022-168410","article-title":"LILRB4 is a novel target for KMT2A rearranged acute leukemia","volume":"140","author":"Smith","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","article-title":"Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia","volume":"59","author":"Albinger","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coph.2025.102546_bib55","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1182\/blood-2022-170712","article-title":"Off-the-Shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib56","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2023-173582","article-title":"A phase 1 study of NKX101, a chimeric antigen receptor natural killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia","volume":"142","author":"Sauter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib57","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib59","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1182\/blood-2023-190561","article-title":"Trials in progress: a phase I\/II clinical trial of off the shelf universal donor natural killer cells combined with chemotherapy for treatment of relapsed\/refractory acute myeloid leukemia (KARMA)","volume":"142","author":"Lamb","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102546_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102336","article-title":"Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:25:46Z","timestamp":1774517146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"alternative-id":["S1471489225000426"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102546","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine and immunotherapeutic approaches for relapsed\/refractory paediatric acute myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102546"}}